Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 8/20 | 0.40 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797693 | 0.85 | MAPK1 (0.44) | IRAK4MKNK1MKNK2MRGPRX1LMNA | |
| SCHEMBL3795962 | 0.85 | MKNK1 (0.44) | IRAK4MKNK1MKNK2MRGPRX1LMNA | |
| SCHEMBL3795968 | 0.85 | MKNK1 (0.44) | IRAK4MKNK1MKNK2MRGPRX1LMNA | |
| SCHEMBL3797145 | 0.85 | MKNK1 (0.44) | IRAK4MKNK1MKNK2MRGPRX1LMNA | |
| SCHEMBL3795880 | 0.83 | MKNK2 (0.49) | MKNK1MKNK2EGFRSRC | |
| SCHEMBL3799692 | 0.82 | RAB9A (0.44) | IRAK4LMNARAB9AEGFRFGFR1 | |
| SCHEMBL3804308 | 0.82 | MKNK2 (0.56) | MKNK1MKNK2 | |
| SCHEMBL3808638 | 0.80 | PIP4K2C (0.53) | IRAK4MKNK2LMNAEGFRPIP4K2C | |
| SCHEMBL3798481 | 0.79 | MKNK2 (0.47) | IRAK4MKNK1MKNK2MRGPRX1LMNA | |
| SCHEMBL16161827 | 0.78 | MKNK2 (0.47) | MKNK1MKNK2EGFRFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | claimed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Boehringer Ingelheim Internationational GmbH (DE) | 2010-09-30 | — | — | US | disclosed |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2010-06-10 | — | — | US | disclosed |
| EP-1899353-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DeveloGen Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136402-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DEVELOGEN AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247517-A1 | USE OF MNK INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | NEK9, TTBK1, NEK2 | IRAK4 1595/4885MKNK1 14/4885MKNK2 11/4885 |
| US-20100143341-A1 | THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, PDXK | IRAK4 1840/4885MKNK1 74/4885MKNK2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.